Advances in siRNA delivery in cancer therapy

References

• Stratton MR, Campbell PJ, Futreal PA. The Cancer genome. Nature. 2009;458:719–724.
   PubMed Web of Science ®Google Scholar
• Jorgensen RA, Cluster PD, English J, et al. Chalcone synthase co suppression phenotypes in petunia flowers: comparison of sense vs. antisense constructs and single-copy vs. complex T-DNA sequences. Plant Mol Biol. 1996;31:957–973.
   PubMed Web of Science ®Google Scholar
• Fire A, Xu S, Montgomery MK, et al. Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans. Nature. 1998;391:806–811.
   PubMed Web of Science ®Google Scholar
• Elbashir SM, Harborth J, Lendeckel W, et al. Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells. Nature. 2001;411:494–498.
   PubMed Web of Science ®Google Scholar
• McCaffrey AP, Meuse L, Pham TT, et al. Gene expression: RNA interference in adult mice. Nature. 2002;418:38–39.
   PubMed Web of Science ®Google Scholar
• Whelan J. First clinical data on RNAi. Drug Discov Today. 2005;10:1014–1015.
   PubMed Web of Science ®Google Scholar
• Davis ME, Zuckerman JE, Choi CH, et al. Evidence of RNAi in humans from systemically administered siRNA via targeted nanoparticles. Nature. 2010;464:1067–1070.
   PubMed Web of Science ®Google Scholar
• Matranga C, Tomari Y, Shin C, et al. Passenger-strand cleavage facilitates assembly of siRNA into Ago2-contaning RNAi enzyme complexes. Cell. 2005;123:607–620.
   PubMed Web of Science ®Google Scholar
• Tolia NH, Joshua-Tor L. Slicer and the Argonautes. Nat Chem Biol. 2007;3:36–43.
   PubMed Web of Science ®Google Scholar
• Ameres SL, Martinez J, Schroeder R. Molecular basis for target RNA recognition and cleavage by human RISC. Cell. 2007;130:101–112.
   PubMed Web of Science ®Google Scholar
• Rand TA, Petersen S, Du F, et al. Argonaute2 cleaves the anti-guide strand of siRNA during RISC activation. Cell. 2005;123:621–629.
   PubMed Web of Science ®Google Scholar
• Dykxhoorn DM, Lieberman J. Knocking down disease with siRNAs. Cell. 2006;126:231–235.
   PubMed Web of Science ®Google Scholar
• Novina CD, Sharp PA. The RNAi revolution. Nature. 2004;430:161–164.
   PubMed Web of Science ®Google Scholar
• Lingel A, Sattler M. Novel modes of protein-RNA recognition in the RNAi pathway. Curr Opin Struct Biol. 2005;15:107–115.
   PubMed Web of Science ®Google Scholar
• Peocot CV, Calin GA, Coleman RL, et al. RNA interference in the clinic: challenges and future directions. Nat Rev Cancer. 2011;11:59–67.
   PubMed Web of Science ®Google Scholar
• Alexis F, Pridgen E, Molnar LK, et al. Factors affecting the clearance and biodistribution of polymeric nanoparticles. Mol Pharm. 2008;5:505–515.
   PubMed Web of Science ®Google Scholar
• Layzer JM, McCaffrey AP, Tanner AK, et al. In vivo activity of nuclease-resistant siRNAs. RNA. 2004;10:766–771.
   PubMed Web of Science ®Google Scholar
• Mosser DM, Edwards JP. Exploring the full spectrum of macrophage activation. Nat Rev Immunol. 2008;8:958–969.
   PubMed Web of Science ®Google Scholar
• Jackson AL, Bartz SR, Schelter J, et al. Expression profiling reveals off-target gene regulation by RNAi. Nat Biotechnol. 2003;21:635–637.
   PubMed Web of Science ®Google Scholar
• Whitehead KA, Langer R, Anderson DG. Knocking down barriers: advances in siRNA delivery. Nat Rev Drug Discov. 2009;8:129–138.
   PubMed Web of Science ®Google Scholar
• Jackson AL, Burchard J, Schelter J, et al. Widespread siRNA ‘off-target’ transcript silencing mediated by seed region sequence complementarily. RNA. 2006;12:1179–1187.
   PubMed Web of Science ®Google Scholar
• Hornung V, Guenthner-Biller M, Bourquin C, et al. Sequence-specific potent induction of IFN-alpha by short interfering RNA in plasmacytoid dendritic cells through TLR7. Nat Med. 2005;11:263–270.
   PubMed Web of Science ®Google Scholar
• Marques JT, Williams BR. Activation of the mammalian immune system by siRNAs. Nat Biotechnol. 2005;23:1399–1405.
   PubMed Web of Science ®Google Scholar
• Kariko K, Bhuyan P, Capodici J, et al. Small interfering RNAs mediate sequence-independent gene suppression and induce immune activation by signaling through toll-like receptor 3. J Immunol. 2004;172:6545–6549.
   PubMed Web of Science ®Google Scholar
• Harborth J, Elbashir SM, Vandenburgh K, et al. Sequence, chemical, and structural variation of small interfering RNAs and short hairpin RNAs and the effect on mammalian gene silencing. Antisense Nucleic Acid Drug Dev. 2003;13:83–10.
   PubMedGoogle Scholar
• Czauderna F, Fechtner M, Dames S, et al. Structural variations and stabilizing modifications of synthetic siRNAs in mammalian cells. Nucleic Acids Res. 2003;31:2705–2716.
   PubMed Web of Science ®Google Scholar
• Liao H, Wang JH. Biomembrane-permeable and ribonuclease-resistant siRNA with enhanced activity. Oligonucleotides . 2005;15:196–205.
   PubMedGoogle Scholar
• Hall AHS, Wan J, Shaughnessy EE, et al. RNA interference using boranophosphate siRNAs: structure-activity relationships. Nucleic Acids Res. 2004;32:5991–6000.
   PubMed Web of Science ®Google Scholar
• Li L, Shen Y. Overcoming obstacles to develop effective and safe siRNA therapeutics. Expert Opin Biol Ther. 2009;9:609–619.
   PubMed Web of Science ®Google Scholar
• Zhang S, Zhao B, Jiang H, et al. Cationic lipids and polymers mediated vectors for delivery of siRNA. J Control Release. 2007;123:1–10.
   PubMed Web of Science ®Google Scholar
• Fenske DB, Cullis PR. Liposomal nanomedicines. Expert Opin Drug Deliv. 2008;5:25–144.
   PubMed Web of Science ®Google Scholar
• Elouahabi A, Ruysshaert JM. Formulation and intracellular trafficking of lipoplexes and polyplexes. Mol Ther. 2005;11:336–347.
   PubMed Web of Science ®Google Scholar
• Sarisozen C, Salzano G, Torchilin VP. Recent advances in siRNA delivery. Biomol Concepts. 2015;6:321–341.
   PubMedGoogle Scholar
• Kim HS, Song IH, Kim JC, et al. In vitro and in vivo gene transferring characteristics of novel cationic lipids, DMKD (O, O′-dimyristyl-N-lysyl aspartate) and DMKE (O,O′-dimyristyl-N-lysyl glutamate). J Control Release. 2006;115:234–241.
   PubMed Web of Science ®Google Scholar
• Santel A, Aleku M, Keil O, et al. A novel siRNA-lipoplex technology for RNA interference in the mouse vascular endothelium. Gene Ther. 2006;1:1222–1234.
   PubMed Web of Science ®Google Scholar
• Dokka S, Toledo D, Shi X, et al. Oxygen radical-mediated pulmonary toxicity induced by some cationic liposomes. Pharm Res. 2000;17:521–525.
   PubMed Web of Science ®Google Scholar
• Spagnou S, Miller AD, Keller M. Lipidic carriers of siRNA: differences in the formulation, cellular uptake, and delivery with plasmid DNA. Biochemistry . 2004;43:13348–13356.
   PubMed Web of Science ®Google Scholar
• Lv H, Zhang S, Wang B, et al. Toxicity of cationic lipids and cationic polymers in gene delivery. J Control Release. 2006;114:100–109.
   PubMed Web of Science ®Google Scholar
• Shim G, Han SE, Yu YH, et al. Trilysinoyl oleylamide-based cationic liposomes for systemic co-delivery of siRNA and an anticancer drug. J Control Release. 2011;155:60–66.
   PubMed Web of Science ®Google Scholar
• Kenny GD, Kamaly N, Kalber TL, et al. Novel multifunctional nanoparticle mediates siRNA tumour delivery, visualisation and therapeutic tumour reduction in vivo. J Control Release. 2011;149:111–116.
   PubMed Web of Science ®Google Scholar
• Gewirtz AM. On future's doorstep: future’s doorstep: RNA interference and the pharmacopeia of tomorrow. J Clin Invest. 2007;117:3612–3614.
   PubMed Web of Science ®Google Scholar
• Landen CN Jr, Chavez-Reyes A, Bucana C, et al. Therapeutics EphA2 gene targeting in vivo using neutral liposomal siRNA delivery. Cancer Res. 2005;65:6910–6918.
   PubMed Web of Science ®Google Scholar
• Halder J, Kamat AA, Landen CN Jr, et al. Focal adhesion kinase targeting using in vivo short interfering RNA delivery in neutral liposomes for ovarian carcinoma therapy. Clin Cancer Res. 2006;12:4916–4924.
   PubMed Web of Science ®Google Scholar
• Gray MJ, Van Buren G, Dallas NA, et al. Therapeutic targeting of neuropilin-2 on colorectal carcinoma cells implanted in the murine liver. J Nat Cancer Inst. 2008;100:109–120.
   PubMedGoogle Scholar
• Soutschek J, Akinc A, Bramlage B, et al. Therapeutic silencing of an endogenous gene by systemic administration of modified siRNAs. Nature. 2004;432:173–178.
   PubMed Web of Science ®Google Scholar
• Rossi JJ. RNAi therapeutics: SNALP siRNAs in vivo. Gene Ther. 2006;13:583–584.
   PubMed Web of Science ®Google Scholar
• Morrissey DV, Lockridge JA, Shaw L, et al. Potent and persistent in vivo anti-HBV activity of chemically modified siRNAs. Nat Biotechnol. 2005;23:1002–1007.
   PubMed Web of Science ®Google Scholar
• Zimmermann TS, Lee HC, Akinc A, et al. RNAi-mediated gene silencing in non-human primates. Nature. 2006;441:111–114.
   PubMed Web of Science ®Google Scholar
• Xu CF, Wang J. Delivery systems for siRNA drug development in cancer therapy. Asian J Pharm Sci. 2015;10:1–12.
   Web of Science ®Google Scholar
• Shen H, Sun T, Ferrari M. Nanovector delivery of siRNA for cancer therapy. Cancer Gene Ther. 2012;19:367–373.
   PubMed Web of Science ®Google Scholar
• Akinc A, Zumbuehl A, Goldberg M, et al. A combinatorial library of lipid-like materials for delivery of RNAi therapeutics. Nat Biotechnol. 2008;26:561–569.
   PubMed Web of Science ®Google Scholar
• Pille JY, Li H, Blot E, et al. Intravenous delivery of anti-RhoA small interfering RNA loaded in nanoparticles of chitosan in mice: safety and efficacy in xenografted aggressive breast cancer. Hum Gene Ther. 2006;17:1019–1026.
   PubMed Web of Science ®Google Scholar
• Noh SM, Han SE, Shim G, et al. Tocopheryloligochitosan-based self-assembling oligomersomes for siRNA delivery. Biomaterials. 2011;32:849–857.
   PubMed Web of Science ®Google Scholar
• Urban-Klein B, Werth S, Abuharbeid S, et al. RNAi-mediated gene targeting through systemic application of polyethylenimine (PEI)-complexed siRNA in vivo. Gene Ther. 2005;12:461–466.
   PubMed Web of Science ®Google Scholar
• Alshamsan A, Hamdy S, Samuel J, et al. The induction of tumor apoptosis in B16 melanoma following STAT3 siRNA delivery with a lipid-substituted polyethlenimine. Biomaterials. 2010;31:1420–1428.
   PubMed Web of Science ®Google Scholar
• Finlay J, Roberts CM, Lowe G, et al. RNA-based TWIST1 inhibition via dendrimer complex to reduce breast cancer cell metastasis. Biomed Res Int. 2015;2015:382745.
   PubMed Web of Science ®Google Scholar
• McNamara JO, II, Andrechek ER, Wang Y. Cell type-specific delivery of siRNAs with aptamer-siRNA chimeras. Nat Biotechnol. 2006;24:1005–1015.
   PubMed Web of Science ®Google Scholar
• Gilboa-Geffen A, Hamar P, Le MT, et al. Gene knockdown by EpCAMaptamer-siRNA chimeras suppresses epithelial breast cancers and their tumor-initiating cells. Mol Cancer Ther. 2015;14:2279–2291.
   PubMed Web of Science ®Google Scholar
• Mao S, Sun W, Kissel T. Chitosan-based formulations for delivery of DNA and siRNA. Adv Drug Deliv Rev. 2010;62:12–27.
   PubMed Web of Science ®Google Scholar
• Davis ME, Brewster ME. Cyclodextrin-based pharmaceutics: past, present and future. Nat Rev Drug Discov. 2004;3:1023–1035.
   PubMed Web of Science ®Google Scholar
• Lieskovan S, Heidel JD, Bartlett DW, et al Sequence-specific knockdown of EWS-FLI1 by targeted, nonviral delivery of small interfering RNA inhibits tumor growth in a murine model of metastatic Ewing's sarcoma. Cancer Res. 2005;65:8984–8992.
   PubMed Web of Science ®Google Scholar
• Kesharwani P, Tekade RK, Gajbhiye V, et al. Cancer targeting potential of some ligand-anchored poly(propylene imine) dendrimers: a comparison. Nanomedicine. 2011;7:295–304.
   PubMed Web of Science ®Google Scholar
• Lee JH, Cha KE, Kim MS, et al. Nanosizedpolyamidoamine (PAMAM) dendrimer-induced apoptosis mediated by mitochondrial dysfunction. Toxicol Lett. 2009;190:202–207.
   PubMed Web of Science ®Google Scholar
• Patil ML, Zhang M, Taratula O, et al. Internally cationic polyamidoamine PAMAM-OH dendrimers for siRNA delivery: effect of the degree of quaternization and cancer targeting. Biomacromolecules. 2009;10:258–266.
   PubMed Web of Science ®Google Scholar
• Taratula O, Garbuzenko OB, Kirkpatrick P, et al. Surface engineered targeted PPI dendrimer for efficient intracellular and intratumoral siRNA delivery. J Control Release. 2009;140:284–293.
   PubMed Web of Science ®Google Scholar
• Jeong JH, Mok H, Oh YK, et al. siRNA conjugate delivery systems. Bioconjug Chem. 2009;20:5–14.
   PubMed Web of Science ®Google Scholar
• Wolfrum C, Shi S, Jayaprakash KN, et al. Mechanism and optimization of in vivo delivery of lipophilic siRNAs. Nat Biotechnol. 2007;25:1149–1157.
   PubMed Web of Science ®Google Scholar
• Meade BR, Dowdy SF. Exogenous siRNA delivery using peptide transduction domains/cell penetrating peptides. Adv Drug Deliv Reviews. 2007;59:134–140.
   PubMed Web of Science ®Google Scholar
• Muratovska A, Eccles MR. Conjugate for efficient delivery of short interfering RNA (siRNA) into mammalian cells. FEBS Lett. 2004;558:63–68.
   PubMed Web of Science ®Google Scholar
• Chiu YL, Ali A, Chu CY, et al. Visualizing a correlation between siRNA localization, cellular uptake, and RNAi in living cells. Chem Bio. 2004;11:1165–1175.
   PubMed Web of Science ®Google Scholar
• Moschos SA, Jones SW, Perry MM, et al. Lung delivery studies using siRNA conjugated to TAT (48–60) and penetratin reveal peptide induced reduction in gene expression and induction of innate immunity. Bioconjugate Chem. 2007;18:1450–1459.
   PubMed Web of Science ®Google Scholar
• Guo P, Coban O, Snead NM, et al. Engineering RNA for targeted siRNA delivery and medical application. Adv Drug Deliv Rev. 2010;62:650–666.
   PubMed Web of Science ®Google Scholar
• Saraswathy M, Gong S. Recent development in the co-delivery of siRNA and small molecule anticancer drugs for cancer treatment. Mater Today. 2014;327:1–9.
   Google Scholar
• Chen AA, Derfus AM, Khetani SR, et al. Quantum dots to monitor RNAi delivery and improving gene silencing. Nucleic Acids Res. 2005;33:190–198.
   PubMed Web of Science ®Google Scholar
• Gao X, Cui Y, Levenson RM, et al. In vivo cancer targeting and imaging with semiconductor quantum dots. Nat Biotechnol. 2004;22:969–976.
   PubMed Web of Science ®Google Scholar
• Lu Q, Moore JM, Huang G, et al. RNA polymer translocation with single-walled carbon nanotubes. Nano Lett. 2004;4:2473–2477.
   Web of Science ®Google Scholar
• Bhatnagar I, Venkatesan J, Kim SK. Polymer functionalized single walled carbon nanotubes mediated drug delivery of gliotoxin in cancer cells. J Biomed Nanotechnol. 2014;10:120–130.
   PubMed Web of Science ®Google Scholar
• Lee JM, Yoon T-J, Cho YS. Recent developments in nanoparticle-based siRNA delivery for cancer therapy. Biomed Res Int. 2013;2013:1–10.
   Web of Science ®Google Scholar
• Kam NW, Liu Z, Dai H. Functionalization of carbon nanotubes via cleavable disulfide bonds for efficient intracellular delivery of siRNA and potent gene silencing. J Am Chem Soc. 2005;127:12492–12493.
   PubMed Web of Science ®Google Scholar
• Kirkpatrick DL, Weiss M, Naumov A, et al. Carbon nanotubes: solution for the therapeutic delivery of siRNA. Materials. 2012;5:278–301.
   PubMed Web of Science ®Google Scholar
• Liu Z, Tabakman S, Welsher K, et al. Carbon nanotubes in biology and medicine: in vitro and in vivo detection, imaging and drug delivery. Nano Res. 2009;2:85–120.
   PubMed Web of Science ®Google Scholar
• Ghosh P, Han G, De M, et al. Gold nanoparticles in delivery applications. Adv Drug Deliv Rev. 2008;60:1307–1315.
   PubMed Web of Science ®Google Scholar
• Song WJ, Du JZ, Sun TM, et al. Gold nanoparticles capped with polyethyleneimine for enhanced siRNA delivery. Small. 2010;6:239–246.
   PubMed Web of Science ®Google Scholar
• Ding Y, Jiang Z, Saha K, et al. Gold Nanoparticles for Nucleic Acid Delivery. Mol Ther. 2014;22:1075–1083.
   PubMed Web of Science ®Google Scholar
• Matzke MA, Matzke AJ. Planting the Seeds of a New Paradigm. PLoS Biol. 2004;2:e133.
   PubMed Web of Science ®Google Scholar